MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock public...
$269,883K
Proceeds from issuance of
common stock public...
$188,880K
Proceeds from issuance of
common stock public...
$119,598K
Proceeds from stock
option exercises
$12,786K
Proceeds from issuance of
common stock for cash...
$243K
Net cash provided by
financing activities
$590,999K
Canceled cashflow
$391K
Net increase in cash
and cash...
$58,830K
Canceled cashflow
$532,169K
Payment of shelf
offering costs
$391K
Maturities of marketable
securities
$425,000K
Stock-based compensation
$19,324K
Prepaid, other current
assets, and other assets
-$2,470K
Accounts payable and
accrued liabilities
$427K
Depreciation and
amortization
$59K
Net cash provided by
(used in) investing...
-$389,753K
Net cash used in
operating activities
-$142,416K
Canceled cashflow
$425,000K
Canceled cashflow
$22,280K
Purchases of marketable
securities
$814,738K
Net loss
-$154,651K
Purchases of property and
equipment
$15K
Accretion of discount on
held-to-maturity securities
$9,879K
Accrued interest
receivable
$166K
Back
Back
Cash Flow
source: myfinsight.com
Mineralys Therapeutics, Inc. (MLYS)
Mineralys Therapeutics, Inc. (MLYS)